ClinicalTrials.gg
RecruitingNCT06831500CARBIDOHUpdated Jan 29, 2026

Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.

A Phase 1/2 interventional study of Administration of Carbidopa/levodopa in Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic and Parkinson Disease, sponsored by Julien Bally. Recruiting at 2 sites in Switzerland. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Julien Bally · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Sex
All
01

Study summary

This study is aimed at patients with multi-system atrophy - parkinsonian type (P-MSA) or Parkinson's disease (PD) receiving dopaminergic drugs and suffering from orthostatic hypotension (OH).

OH is a drop in blood pressure when standing, which can lead to symptoms of dizziness, lightheadedness, a black veil in front of the eyes and, when severe, can lead to fainting. HO is one of the symptoms present in AMS-P and PD.

The standard treatment for parkinsonian symptoms of slowness and stiffness is the administration of antiparkinsonian drugs containing dopamine. These dopaminergic drugs always contain 1) levodopa (which is the precursor of dopamine) and 2) an enzyme inhibitor, which may be either benserazide (in the case of Madopar® and its generics) or carbidopa (in the case of Sinemet® or Stalevo® and their generics) and whose role is to potentiate the effect of levodopa.

It has long been known that dopaminergic drugs aggravate HO. Through various mechanisms, this worsening of HO is linked as much to levodopa as to the enzyme inhibitor with which it is combined. However, investigators do not know the respective effects of these two molecules on HO.

In this study, investigators examine how the ratio of Carbidopa to levodopa affects HO in the various assays of the dopaminergic drug under study.

02

Conditions studied

  • Multi-system Atrophy - Parkinsonian Type
  • Orthostatic Hypotension, Dysautonomic
  • Parkinson Disease

Keywords

  • CARBIDOH
03

In context

Shy-Drager Syndrome

33 studies on the registry are indexed under Shy-Drager Syndrome; 15 are open to participants now.

This study's planned enrollment of 36 is below the median of 41 across 24 interventional studies indexed under Shy-Drager Syndrome.

Browse Shy-Drager Syndrome studies →

Lead sponsor

This is the only study on the registry with Julien Bally as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. form signed.
  2. Patient over 18 years and under 80 years of age.
  3. Patient with Multiple System Atrophy- Parkinsonian type (MSA-P) (confirmed by diagnostic criteria for clinically established and clinically probable multiple system atrophy (11); OR Patient with Parkinson Disease (PD) (12) presenting OH symptoms (getting at least one point at the 3 questions - n° 14, 15 and 16 - of the SCOPA-AUT scale that address orthostatic hypotension symptoms).
  4. Patient currently receiving Dopamine-Replacement Therapy (i.e. Levodopa combined with Carbidopa or Benserazide).

Exclusion criteria

Exclusion Criteria:

  1. Patient unable to stand an overnight (at least 12 hours) withdrawal of their immediate-release DRT (last extended-, delayed-, or controlled-release dosage must be taken minimum 24 hours prior to the test).
  2. Patient with known congestive heart failure, grades C and D, III and IV.
  3. Patient with dementia (i.e. major cognitive impairment) associated to MSA-P or PD,
  4. Patient with mild cognitive impairment, and unable to provide or understand , i.e. who does not have full capacity for discernment.
  5. Current participation to other clinical trials.
  6. Pregnant or lactating woman or willing to become pregnant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    Ratio 1:10 i.e. 20 mg Carbidopa / 200 mg Levodopa

    This Carbidopa / Levodopa IMP ratio will be administered as a single dose, orally, at visit 1 or 2 or 3 (random order).

    Drug: Administration of Carbidopa/levodopa

  • Active comparator
    Ratio 1:4 i.e. 50 mg Carbidopa / 200 mg Levodopa

    This Carbidopa / Levodopa IMP ratio will be administered as a single dose, orally, at visit 1 or 2 or 3 (random order).

    Drug: Administration of Carbidopa/levodopa

  • Experimental
    Ratio 1:2 i.e. 100 mg Carbidopa / 200 mg Levodopa

    This Carbidopa / Levodopa IMP ratio will be administered as a single dose, orally, at visit 1 or 2 or 3 (random order).

    Drug: Administration of Carbidopa/levodopa

Interventions

  • DrugAdministration of Carbidopa/levodopa

    Participants will perform beat-by-beat orthostatic tests (Schellong tests) before and after intake of single doses of carbidopa:levodopa combinations at 3 different ratios

06

What researchers measure

Primary outcomes

  1. Feasibility of future large-scale double-blind randomized controlled trial (RCT)

    The primary objective is to investigate the feasibility of conducting a future large-scale double-blind randomized controlled trial (RCT) assessing the effect on orthostatic hypotension (OH) of different dosages of Carbidopa (20, 50 or 100 mg), for a constant Levodopa dose (200 mg) through: * Recruitment rate: Mean number of patients informed per month during the recruitment period, % of patients wiling to participate to the study among the informed patients, % of patients eligible among the informed patients * Adherence rate:% of patients completing the study intervention period among randomized patients * Retention rate:% of patients showing up at the last follow-up visit among patients who have completed the study intervention period, % of drop-outs among randomized patients at last follow-up visit * Data completion rate of the therapeutic effect measures: % of patients with analysable OH data at week 1, 2 and 3.

    Time frame: From enrollment to the end of study at 5 weeks.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Nov 2026, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 18, 2025
StartActual
Jul 18, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06831500
Lead sponsor
Julien Bally
Responsible party
Julien Bally (Principal Investigator and Head of the Movement Disorder Unit in the department of Clinical Neurosciences (CHUV), University of Lausanne Hospitals) — Sponsor-investigator
First posted
Feb 18, 2025
Start date
Jul 18, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jan 29, 2026

Study contacts

Julien BALLY, Dr PD-MER
Contact
julien.bally@chuv.ch
+41 79 556 78 19

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion